This week, the ratings of 5 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a D to a F rating, Mylan N.V. (MYL) takes a hit this week. Mylan N.V. is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

SteadyMed Ltd. (STDY) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of STDY stock.

Cardiome Pharma Corp. (CRME) declines this week from a D to a F. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This week, Imprimis Pharmaceuticals, Inc. (IMMY) drops from a D to a F rating. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically delivered medications. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMY stock.

Pulmatrix Inc (PULM) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PULM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.